Discovery of Histamine H3 Antagonists for the Treatment of Cognitive Disorders and Alzheimer’s Disease
Authors:
- Jorge D. BrioniJBJorge D. Brioni
- Tim A. EsbenshadeTETim A. Esbenshade
- Tiffany Runyan GarrisonTGTiffany Runyan Garrison
- Scott R. BitnerSBScott R. Bitner
- Marlon D. CowartMCMarlon D. Cowart
- 1 January 2011
- journal article
- review article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 336 (1) , 38-46
Abstract
H3 antagonists increase the release of brain histamine, acetylcholine, noradrenaline, and dopamine, neurotransmitters that are known to modulate cognitive processes. The ability to release brain histamine supports the effect on attention and vigilance, but histamine also modulates other cognitive domains such as short-term and long-term memory. A number of H3 antagonists, including 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine hydrochloride (BF2.649), (1R,3R)-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]cyclobutane-1-carboxamide (PF-03654746), 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide hydrochloride (GSK189254), MK-0249 (structure not yet disclosed), JNJ-17216498 (structure not yet disclosed), and ABT-288 (structure not yet disclosed), have advanced to the clinical area for the potential treatment of human cognitive disorders. H3 antagonists exhibited wake-promoting effects in humans and efficacy in narcoleptic patients, indicating target engagement, but some of them were not efficacious in patients suffering from attention-deficit hyperactivity disorder and schizophrenic patients. Preclinical studies have also shown that H3 antagonists activate intracellular signaling pathways that may improve cognitive efficacy and disease-modifying effects in Alzheimer's disease. Ongoing clinical studies will be able to determine the utility of H3 antagonists for the treatment of cognitive disorders in humans.Keywords
This publication has 51 references indexed in Scilit:
- Evaluation of11C-GSK189254 as a Novel Radioligand for the H3Receptor in Humans Using PETJournal of Nuclear Medicine, 2010
- Selective α7 nicotinic acetylcholine receptor activation regulates glycogen synthase kinase3β and decreases tau phosphorylation in vivoBrain Research, 2009
- Constitutive activity of the histamine H3 receptorTrends in Pharmacological Sciences, 2007
- Molecular aspects of the histamine H3 receptorBiochemical Pharmacology, 2007
- Histamine H3 receptor antagonists: From target identification to drug leadsBiochemical Pharmacology, 2007
- Histaminergic Control of Sleep-Wake Cycles: Recent Therapeutic Advances for Sleep and Wake DisordersCNS & Neurological Disorders - Drug Targets, 2007
- Acute wake‐promoting actions of JNJ‐5207852, a novel, diamine‐based H3 antagonistBritish Journal of Pharmacology, 2004
- On Neurodegenerative Diseases, Models, and Treatment Strategies: Lessons Learned and Lessons Forgotten a Generation Following the Cholinergic HypothesisExperimental Neurology, 2000
- Inhibition of cortical acetylcholine release and cognitive performance by histamine H3 receptor activation in ratsBritish Journal of Pharmacology, 1996
- Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptorNature, 1983